GB0211118D0 - Vaccines - Google Patents

Vaccines

Info

Publication number
GB0211118D0
GB0211118D0 GBGB0211118.5A GB0211118A GB0211118D0 GB 0211118 D0 GB0211118 D0 GB 0211118D0 GB 0211118 A GB0211118 A GB 0211118A GB 0211118 D0 GB0211118 D0 GB 0211118D0
Authority
GB
United Kingdom
Prior art keywords
glucan
antibodies
protective
presented
protective efficacy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0211118.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GBGB0211118.5A priority Critical patent/GB0211118D0/en
Publication of GB0211118D0 publication Critical patent/GB0211118D0/en
Priority to CA2485847A priority patent/CA2485847C/en
Priority to DE60336027T priority patent/DE60336027D1/de
Priority to EP07075796A priority patent/EP1891970B1/en
Priority to DK03730424T priority patent/DK1506009T3/da
Priority to DE60320979T priority patent/DE60320979D1/de
Priority to AT07075796T priority patent/ATE497781T1/de
Priority to PT03730424T priority patent/PT1506009E/pt
Priority to JP2004505087A priority patent/JP5110767B2/ja
Priority to CA2830619A priority patent/CA2830619A1/en
Priority to HK05102699.5A priority patent/HK1069125B/en
Priority to ES03730424T priority patent/ES2306871T3/es
Priority to AT03730424T priority patent/ATE395080T1/de
Priority to AU2003241104A priority patent/AU2003241104A1/en
Priority to PCT/IB2003/002460 priority patent/WO2003097091A2/en
Priority to US10/514,483 priority patent/US20050208079A1/en
Priority to SI200331275T priority patent/SI1506009T1/sl
Priority to EP03730424A priority patent/EP1506009B1/en
Priority to US11/701,250 priority patent/US7824688B2/en
Priority to CY20081100809T priority patent/CY1108234T1/el
Priority to HK08109548.0A priority patent/HK1114335B/en
Priority to JP2009294467A priority patent/JP2010131017A/ja
Priority to US12/854,248 priority patent/US8398990B2/en
Priority to JP2012166700A priority patent/JP5684758B2/ja
Priority to US13/777,903 priority patent/US8679506B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0211118.5A 2002-05-15 2002-05-15 Vaccines Ceased GB0211118D0 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GBGB0211118.5A GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines
EP03730424A EP1506009B1 (en) 2002-05-15 2003-05-15 Beta-glucan-based anti-fungal vaccines
AT03730424T ATE395080T1 (de) 2002-05-15 2003-05-15 Impfstoffe gegen pilzen aus beta-glucan
PCT/IB2003/002460 WO2003097091A2 (en) 2002-05-15 2003-05-15 Glucan-based vaccines
EP07075796A EP1891970B1 (en) 2002-05-15 2003-05-15 Beta glucan-based vaccines free of mannoprotein
DK03730424T DK1506009T3 (da) 2002-05-15 2003-05-15 Beta-glucan-baserede antisvampevacciner
DE60320979T DE60320979D1 (de) 2002-05-15 2003-05-15 Impfstoffe gegen Pilzen aus Beta-Glucan
AT07075796T ATE497781T1 (de) 2002-05-15 2003-05-15 Impfstoffe auf mannoproteinfreier beta-glucan- basis
PT03730424T PT1506009E (pt) 2002-05-15 2003-05-15 Vacinas anti-fúngicas baseadas em beta-glucanos
JP2004505087A JP5110767B2 (ja) 2002-05-15 2003-05-15 グルカンベースのワクチン
CA2830619A CA2830619A1 (en) 2002-05-15 2003-05-15 Glucan-based vaccines
HK05102699.5A HK1069125B (en) 2002-05-15 2003-05-15 Beta-glucan-based anti-fungal vaccines
ES03730424T ES2306871T3 (es) 2002-05-15 2003-05-15 Vacunas antifungicas a base de beta-glucano.
CA2485847A CA2485847C (en) 2002-05-15 2003-05-15 Glucan-based vaccines
AU2003241104A AU2003241104A1 (en) 2002-05-15 2003-05-15 Glucan-based vaccines
DE60336027T DE60336027D1 (de) 2002-05-15 2003-05-15 Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis
US10/514,483 US20050208079A1 (en) 2002-05-15 2003-05-15 Glucan-based vaccines
SI200331275T SI1506009T1 (sl) 2002-05-15 2003-05-15 Proti gljivne vakcine na osnovi beta glukana
US11/701,250 US7824688B2 (en) 2002-05-15 2007-02-01 Glucan-based vaccines
CY20081100809T CY1108234T1 (el) 2002-05-15 2008-07-31 Αντι-μυκητικα εμβολια βασιζομενα σε βητα-γλυκανη
HK08109548.0A HK1114335B (en) 2002-05-15 2008-08-27 Beta glucan-based vaccines free of mannoprotein
JP2009294467A JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン
US12/854,248 US8398990B2 (en) 2002-05-15 2010-08-11 Glucan-based vaccines
JP2012166700A JP5684758B2 (ja) 2002-05-15 2012-07-27 グルカンベースのワクチン
US13/777,903 US8679506B2 (en) 2002-05-15 2013-02-26 Glucan-based vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0211118.5A GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines

Publications (1)

Publication Number Publication Date
GB0211118D0 true GB0211118D0 (en) 2002-06-26

Family

ID=9936711

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0211118.5A Ceased GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines

Country Status (14)

Country Link
US (4) US20050208079A1 (enExample)
EP (2) EP1506009B1 (enExample)
JP (3) JP5110767B2 (enExample)
AT (2) ATE497781T1 (enExample)
AU (1) AU2003241104A1 (enExample)
CA (2) CA2485847C (enExample)
CY (1) CY1108234T1 (enExample)
DE (2) DE60336027D1 (enExample)
DK (1) DK1506009T3 (enExample)
ES (1) ES2306871T3 (enExample)
GB (1) GB0211118D0 (enExample)
PT (1) PT1506009E (enExample)
SI (1) SI1506009T1 (enExample)
WO (1) WO2003097091A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
ATE508362T1 (de) * 2004-04-05 2011-05-15 Univ Bordeaux 2 Peptide und peptidmimetika die an cd23 binden
GB0420466D0 (en) * 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
EP1984004A4 (en) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer THE THERAPY REINFORCING GLUCAN
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007127668A2 (en) * 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
WO2008057501A2 (en) * 2006-11-06 2008-05-15 Whitehead Institute Immunomodulating compositions and methods of use thereof
AU2013203785B2 (en) * 2006-11-06 2016-11-17 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
JP4687644B2 (ja) 2006-12-22 2011-05-25 富士ゼロックス株式会社 画像処理装置、画像読取装置及び画像形成装置
ES2599908T3 (es) * 2007-11-26 2017-02-06 Glaxosmithkline Biologicals Sa Glucanos beta-1,3-enlazados conjugados
CA2706617A1 (en) * 2007-11-26 2009-06-25 Novartis Ag Adjuvanted glucans
MX2010011788A (es) * 2008-04-29 2011-05-30 Immunexcite Inc Composiciones inmunomoduladoras y metodos de uso de las mismas.
EP2331127A2 (en) 2008-09-18 2011-06-15 Novartis AG Vaccine adjuvant combinations
NL1036661C2 (en) 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
JP2012520289A (ja) * 2009-03-10 2012-09-06 パルメッド テバ リミテッド 新規なコプリヌス・コマトゥスおよびトレメッラ・メセンテリカキノコ菌株、それらの生産物および抽出物、ならびにそれらを含む組成物
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
NZ603340A (en) * 2010-05-14 2014-04-30 Alltech Inc Yeast cell wall components and detection thereof
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
EP2652511B8 (en) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Flow cytometry analysis of materials adsorbed to metal salts
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
CN104203946B (zh) 2012-03-07 2017-03-22 诺华股份有限公司 免疫上有用的精氨酸盐
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
JP6416751B2 (ja) 2012-04-30 2018-10-31 バイオセラ インコーポレイテッド β−グルカン免疫治療方法
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
AU2014241492A1 (en) 2013-03-12 2015-09-17 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
EP3613755A1 (en) 2013-07-11 2020-02-26 Novartis AG Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
CA2932192C (en) * 2013-12-05 2020-10-06 Biothera, Inc. .beta.-glucan assay methods
MX381376B (es) * 2015-01-26 2025-03-12 Kaleido Biosciences Inc Preparaciones terapéuticas de glicanos y métodos relacionados con estas.
CN104771498A (zh) * 2015-03-13 2015-07-15 臧海阳 一种治疗热毒蕴结型痄腮的中药组合物
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
KR102795692B1 (ko) * 2018-01-19 2025-04-16 밀테니 비오텍 비.브이. & 씨오. 케이지 키메라 항원 수용체를 발현하는 조절 t 세포
US11701417B2 (en) * 2019-03-27 2023-07-18 West Virginia University Vaccine formulation to protect against pertussis
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
AU2023223603A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.
CA3243638A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg CONJUGATED CONSISTING OF OR COMPRISING AT LEAST ONE SS-GLUCANE OR ONE MANNANE

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466289B (sv) * 1984-09-19 1992-01-27 James Hoffman Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning
JPS6383012A (ja) * 1986-09-26 1988-04-13 Nonogawa Shoji:Kk 化粧料
AU650626B2 (en) * 1989-09-08 1994-06-30 Alpha-Beta Technology, Inc. Method for producing soluble glucans
EP0471954A3 (en) 1990-08-13 1993-03-03 American Cyanamid Company Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ES2231770T3 (es) * 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
CN1094288A (zh) * 1993-04-23 1994-11-02 福建省微生物研究所 利用红色诺卡氏菌制造细胞壁骨架粉末的方法
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
JPH09309842A (ja) * 1996-05-20 1997-12-02 Kureha Chem Ind Co Ltd 新規な生理活性物質、その製造方法及び医薬組成物
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4230635B2 (ja) 2000-02-29 2009-02-25 富士フイルム株式会社 デジタルカメラ

Also Published As

Publication number Publication date
CY1108234T1 (el) 2014-02-12
US20110059120A1 (en) 2011-03-10
ATE497781T1 (de) 2011-02-15
CA2830619A1 (en) 2003-11-27
JP5684758B2 (ja) 2015-03-18
JP2012224636A (ja) 2012-11-15
US7824688B2 (en) 2010-11-02
WO2003097091A3 (en) 2004-03-04
US8398990B2 (en) 2013-03-19
EP1506009A2 (en) 2005-02-16
CA2485847C (en) 2013-12-31
US20070141088A1 (en) 2007-06-21
JP5110767B2 (ja) 2012-12-26
US8679506B2 (en) 2014-03-25
WO2003097091A2 (en) 2003-11-27
DK1506009T3 (da) 2008-09-01
JP2005535298A (ja) 2005-11-24
US20050208079A1 (en) 2005-09-22
US20130171187A1 (en) 2013-07-04
AU2003241104A1 (en) 2003-12-02
HK1114335A1 (en) 2008-10-31
CA2485847A1 (en) 2003-11-27
SI1506009T1 (sl) 2008-10-31
PT1506009E (pt) 2008-08-14
DE60320979D1 (de) 2008-06-26
HK1069125A1 (en) 2005-05-13
EP1891970A1 (en) 2008-02-27
JP2010131017A (ja) 2010-06-17
EP1891970B1 (en) 2011-02-09
EP1506009B1 (en) 2008-05-14
DE60336027D1 (de) 2011-03-24
ES2306871T3 (es) 2008-11-16
ATE395080T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
GB0211118D0 (en) Vaccines
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
EP2289549A3 (en) Immunoconjugates for treating cancer
CA2338358A1 (en) Compounds and compositions for delivering active agents
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
AU2001257444A1 (en) Methods and compositions for enhancing cellular function through protection of tissue components
WO2000007979A3 (en) Compounds and compositions for delivering active agents
AU2274201A (en) Compounds and compositions for delivering active agents
CA2333601A1 (en) Surfactant for use in external preparations for skin and external preparation for skin containing the same
EP4295917A3 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
HK1041209A1 (zh) 加強藥物療效的成份及方法
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
WO2004113422A3 (en) Drug delivery device comprising an active compound and method for releasing an active compound from a drug delivery device
AU2525301A (en) Genus leontopodium plant extract and compositions containing same
WO2002032378A3 (en) Fusion cells and cytokine compositions for treatment of disease
WO2003082926A3 (en) Antimicrobial polymer conjugates
WO2000074649A3 (en) Ophthalmic histamine compositions and uses thereof
WO2003009859A1 (en) Immunotherapy for humans
WO2001040442A8 (en) Novel bacterial isolate and the preparation and use of its active metabolites
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
WO2004006851A3 (en) Mycoplasma gallisepticum formulation
WO2002055022A3 (en) Active metabolite of antifungal compound
WO2003007878A3 (en) Antifungal agents of sordarin derivatives
WO2003077885A3 (en) Free-base formulations of local anesthetics
PL342541A1 (en) Fungicides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)